ProShares UltraPro S&P500 (UPRO) Stock Price Today
Aura AI Summary
Key Stats
- $4.89BMarket Cap
- 3,289,519Volume
- Leveraged / InverseSector
- $157.6652W High
- $89.2952W Low
- 33 DaysTypical Hold Time
- -Enterprise Value
- -Div Yield
- 94% Sell | 6% BuyTrading Activity
Track ProShares UltraPro S&P500 (UPRO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, ProShares UltraPro S&P500 has traded between a low of $89.29 and a high of $157.66, highlighting its annual price range. Buy and sell ProShares UltraPro S&P500 shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Most Recent News
Trogenix appoints John Young as Chair and Josh Murray as Non-Executive Director to boost global growth and US expansion.
Trogenix, a clinical-stage precision oncology company, has appointed John Young as Chair and Josh Murray as Non-Executive Director to support its global strategy, commercial growth, and US expansion. John Young brings over 35 years of pharmaceutical ...

Wellington Management Group crosses 5% voting rights threshold in Admiral Group PLC shares.
Wellington Management Group LLP has notified that it crossed the 5% voting rights threshold in Admiral Group PLC as of November 6, 2026. The group holds a total of 5.01% voting rights through direct shares and financial instruments. This disclosure i...

Roche unveils new Alzheimer’s drug and diagnostic data at CTAD 2026, advancing treatment and early detection.
Roche presented new data on its Alzheimer’s disease portfolio at the CTAD 2026 conference, highlighting advances in both pharmaceuticals and diagnostics. Key updates include Phase Ib/IIa data for trontinemab showing rapid amyloid clearance, the start...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.